Intra Cellular Therapies reported $848.34M in Current Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 542.22M 75.6M
Biogen BIIB:US $ 9740.9M 1825M
Bristol Myers Squibb BMY:US $ 30186M 65M
Cytokinetics CYTK:US $ 602.25M 21.28M
Esperion Therapeutics ESPR:US $ 252.48M 38.34M
Gilead Sciences GILD:US $ 13705M 1076M
Halozyme Therapeutics HALO:US $ 988.69M 62.4M
Intra Cellular Therapies ITCI:US $ 848.34M 381.06M
JAZZ PHA JAZZ:US $ 2590.83M 89.98M
Marinus Pharmaceuticals MRNS:US $ 135.07M 3.39M
Minerva Neurosciences NERV:US $ 55.7M 6.5M
Nektar Therapeutics NKTR:US $ 665.54M 67.92M
Neurocrine Biosciences NBIX:US $ 1019.3M 1.1M
Novartis NVS:US $ 38142M 906M
Prothena PRTA:US 555.62M 29.19M
Redhill Biopharma RDHL:US $ 72.58M 16.58M
Supernus Pharmaceuticals SUPN:US $ 625.12M 56.6M
United Therapeutics UTHR:US $ 2684.3M 97.7M
Vanda Pharmaceuticals VNDA:US $ 496.9M 4.63M